INTERCEPT Safety Evaluation on Whole Blood

首次发布于 2019 年 7 月 15 日

INTERCEPT Safety Evaluation in Anemic Patients

首次发布于 2018 年 4 月 3 日

A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma

计划入组 14 人 · 首次发布于 2014 年 12 月 8 日

Thalidomide inhalation (Vicore Pharma)

Ezetimibe/obicetrapib (NewAmsterdam Pharma)

DiPOA (Purdue Pharma)

INTERCEPT PHARMACEUTICALS, INC.

United States

INTERCEPT PHARMACEUTICALS INC

United States

Bioprojet Pharma

Belgium

Intercept Pharmaceuticals Voluntarily Withdraws OCALIVA from US Market Following FDA Request

Intercept Pharmaceuticals Withdraws Ocaliva from U.S. Market Following FDA Safety Directive

NASH Treatment Market to Reach Significant Growth by 2032, Driven by Emerging Therapies